The year in arrhythmias-2009: Part I

Heart Rhythm

Volumn 7, Issue 3, 2010, Pages 417-426

  Olshansky, Brian ^a   Delmar, Mario ^b   Tomaselli, Gordon F ^c  

^a UNIVERSITY OF IOWA   (United States)

^b Division of Cardiovascular Medicine   (United States)

^c Donald W Reynolds Cardiovascular Clinical Research Center   (United States)

Author keywords

Ablation; Antiarrhythmic therapy; Atrial fibrillation; Atrial flutter; Supraventricular tachycardia; Ventricular fibrillation; Ventricular tachycardia

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTICOAGULANT AGENT; ATI 5923; CLOPIDOGREL; DABIGATRAN; DIGOXIN; DOFETILIDE; DRONEDARONE; FLECAINIDE; MICRORNA; PLACEBO; PROPAFENONE; QUINIDINE; RAMIPRIL; RANOLAZINE; SOTALOL; SPIRONOLACTONE; TECARFARIN; UNCLASSIFIED DRUG; WARFARIN;

ANTICOAGULATION; ARTICLE; BLEEDING; CATHETER ABLATION; CLINICAL TRIAL; ELECTROCARDIOGRAM; ELECTROGRAPHY; ELECTROPHYSIOLOGY; EMBOLISM; HEART ATRIUM FIBRILLATION; HEART PACING; HEART RHYTHM; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; LOW DRUG DOSE; MACROMOLECULE; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; RECORDING; STENT THROMBOSIS; STROKE; SUPRAVENTRICULAR TACHYCARDIA; UNSPECIFIED SIDE EFFECT;

ARRHYTHMIAS, CARDIAC; ATRIAL FIBRILLATION; HUMANS;

EID: 76949086931     PISSN: 15475271     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hrthm.2009.12.011     Document Type: Article

References (100)

1. Chagot B., Potet F., Balser J.R., and Chazin W.J. Solution NMR structure of the C-terminal EF-hand domain of human cardiac sodium channel NaV1.5. J Biol Chem 284 (2009) 6436-6445
2. Miloushev V.Z., Levine J.A., Arbing M.A., Hunt J.F., Pitt G.S., and Palmer III A.G. Solution structure of the NaV1.2 C-terminal EF-hand domain. J Biol Chem 284 (2009) 6446-6454
3. Biswas S., DiSilvestre D., Tian Y., Halperin V.L., and Tomaselli G.F. Calcium-mediated dual-mode regulation of cardiac sodium channel gating. Circ Res 104 (2009) 870-878
4. 2+* calmodulins. Proc Natl Acad Sci U S A 106 (2009) 5135-5140
5. Walsh C.P., Davies A., Nieto-Rostro M., Dolphin A.C., and Kitmitto A. Labelling of the 3D structure of the cardiac L-type voltage-gated calcium channel. Channels (Austin) 3 (2009) [Epub ahead of print]
6. Bouvier D., Spagnol G., Chenavas S., et al. Characterization of the structure and intermolecular interactions between the connexin40 and connexin43 carboxyl terminal and cytoplasmic loop domains. J Biol Chem 284 (2009) 34257-34271
7. Maeda S., Nakagawa S., Suga M., et al. Structure of the connexin 26 gap junction channel at 3.5 Å resolution. Nature 458 (2009) 597-602
8. Nilsson Jr. K.R., and Bennett V. Ankyrin-based patterning of membrane microdomains: new insights into a novel class of cardiovascular diseases. J Cardiovasc Pharmacol 54 (2009) 106-115
9. Davis L., Abdi K., Machius M., et al. Localization and structure of the ankyrin-binding site on beta2-spectrin. J Biol Chem 284 (2009) 6982-6987
10. Hashemi S.M., Hund T.J., and Mohler P.J. Cardiac ankyrins in health and disease. J Mol Cell Cardiol 47 (2009) 203-209
11. ATP channel C-terminal motif in membrane targeting and metabolic regulation. Proc Natl Acad Sci U S A 106 (2009) 16669-16674
12. Hund T.J., Wright P.J., Dun W., Snyder J.S., Boyden P.A., and Mohler P.J. Regulation of the ankyrin-B-based targeting pathway following myocardial infarction. Cardiovasc Res 81 (2009) 742-749
13. Asimaki A., Tandri H., Huang H., et al. A new diagnostic test for arrhythmogenic right ventricular cardiomyopathy. N Engl J Med 360 (2009) 1075-1084
14. Sato P.Y., Musa H., Coombs W., et al. Loss of plakophilin-2 expression leads to decreased sodium current and slower conduction velocity in cultured cardiac myocytes. Circ Res 105 (2009) 523-526
15. Xu C., Lu Y., Pan Z., et al. The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes. J Cell Sci 120 (2007) 3045-3052
16. Lu Y., Zhang Y., Shan H., et al. MicroRNA-1 downregulation by propranolol in a rat model of myocardial infarction: a new mechanism for ischaemic cardioprotection. Cardiovasc Res 84 (2009) 434-441
17. Luo X., Lin H., Pan Z., et al. Down-regulation of miR-1/miR-133 contributes to re-expression of pacemaker channel genes HCN2 and HCN4 in hypertrophic heart. J Biol Chem 283 (2008) 20045-20052
18. Terentyev D., Belevych A.E., Terentyeva R., et al. miR-1 overexpression enhances Ca(2+) release and promotes cardiac arrhythmogenesis by targeting PP2A regulatory subunit B56alpha and causing CaMKII-dependent hyperphosphorylation of RyR2. Circ Res 104 (2009) 514-521
19. Callis T.E., Pandya K., Seok H.Y., et al. MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice. J Clin Invest 119 (2009) 2772-2786
20. Stambler B.S., Laurita K.R., Shroff S.C., Hoeker G., and Martovitz N.L. Aldosterone blockade attenuates development of an electrophysiological substrate associated with ventricular tachyarrhythmias in heart failure. Heart Rhythm 6 (2009) 776-783
21. Qu J., Volpicelli F.M., Garcia L.I., et al. Gap junction remodeling and spironolactone-dependent reverse remodeling in the hypertrophied heart. Circ Res 104 (2009) 365-371
22. Belluzzi F., Sernesi L., Preti P., Salinaro F., Fonte M.L., and Perlini S. Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients. J Am Coll Cardiol 53 (2009) 24-29
23. Makkar K.M., Sanoski C.A., and Spinler S.A. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias. Pharmacotherapy 29 (2009) 31-48
24. Kruse M., Schulze-Bahr E., Corfield V., et al. Impaired endocytosis of the ion channel TRPM4 is associated with human progressive familial heart block type I. J Clin Invest 119 (2009) 2737-2744
25. Robertson G.A. Endocytic control of ion channel density as a target for cardiovascular disease. J Clin Invest 119 (2009) 2531-2534
26. + channel Kv1.5. Circ Res 104 (2009) 1390-1398
27. Watanabe H., Chopra N., Laver D., et al. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med 15 (2009) 380-383
28. Aizer A., Gaziano J.M., Cook N.R., Manson J.E., Buring J.E., and Albert C.M. Relation of vigorous exercise to risk of atrial fibrillation. Am J Cardiol 103 (2009) 1572-1577
29. Rosengren A., Hauptman P.J., Lappas G., Olsson L., Wilhelmsen L., and Swedberg K. Big men and atrial fibrillation: effects of body size and weight gain on risk of atrial fibrillation in men. Eur Heart J 30 (2009) 1113-1120
30. Schnabel R.B., Sullivan L.M., Levy D., et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet 373 (2009) 739-745
31. Roten L., Rimoldi S.F., Schwick N., et al. Gender differences in patients referred for atrial fibrillation management to a tertiary center. Pacing Clin Electrophysiol 32 (2009) 622-626
32. Kaab S., Darbar D., van Noord C., et al. Large scale replication and meta-analysis of variants on chromosome 4q25 associated with atrial fibrillation. Eur Heart J 30 (2009) 813-819
33. Cheng S., Keyes M.J., Larson M.G., et al. Long-term outcomes in individuals with prolonged PR interval or first-degree atrioventricular block. JAMA 301 (2009) 2571-2577
34. Workman A.J., Pau D., Redpath C.J., et al. Atrial cellular electrophysiological changes in patients with ventricular dysfunction may predispose to AF. Heart Rhythm 6 (2009) 445-451
35. Roberts-Thomson K.C., Kistler P.M., Sanders P., et al. Fractionated atrial electrograms during sinus rhythm: relationship to age, voltage, and conduction velocity. Heart Rhythm 6 (2009) 587-591
36. Yamazaki M., Vaquero L.M., Hou L., et al. Mechanisms of stretch-induced atrial fibrillation in the presence and the absence of adrenocholinergic stimulation: interplay between rotors and focal discharges. Heart Rhythm 6 (2009) 1009-1017
37. Swartz M.F., Fink G.W., Lutz C.J., et al. Left versus right atrial difference in dominant frequency, K(+) channel transcripts, and fibrosis in patients developing atrial fibrillation after cardiac surgery. Heart Rhythm 6 (2009) 1415-1422
38. Dorian P., Guerra P.G., Kerr C.R., et al. Validation of a new simple scale to measure symptoms in atrial fibrillation: the Canadian Cardiovascular Society Severity in Atrial Fibrillation scale. Circ Arrhythm Electrophysiol 2 (2009) 218-224
39. Groenveld H.F., Crijns H.J., Rienstra M., Van den Berg M.P., Van Veldhuisen D.J., and Van Gelder I.C. Does intensity of rate control influence outcome in persistent atrial fibrillation?. Data of the RACE study. Am Heart J 158 (2009) 785-791
40. Nieuwlaat R., Eurlings L.W., Cleland J.G., et al. Atrial fibrillation and heart failure in cardiology practice: reciprocal impact and combined management from the perspective of atrial fibrillation: results of the Euro Heart Survey on atrial fibrillation. J Am Coll Cardiol 53 (2009) 1690-1698
41. Ahmadi-Kashani M., Kessler D.J., Day J., et al. Heart rate predicts outcomes in an implantable cardioverter-defibrillator population. Circulation 120 (2009) 2040-2045
42. Sarrazin J.F., Labounty T., Kuhne M., et al. Impact of radiofrequency ablation of frequent post-infarction premature ventricular complexes on left ventricular ejection fraction. Heart Rhythm 6 (2009) 1543-1549
43. Sullivan R.M., and Olshansky B. Treatment of PVCs post-myocardial infarction: will we get fooled again?. Heart Rhythm 6 (2009) 1550-1551
44. Medi C., Kalman J.M., Haqqani H., et al. Tachycardia-mediated cardiomyopathy secondary to focal atrial tachycardia: long-term outcome after catheter ablation. J Am Coll Cardiol 53 (2009) 1791-1797
45. Corley S.D., Epstein A.E., DiMarco J.P., et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 109 (2004) 1509-1513
46. Friberg L., Hammar N., Edvardsson N., and Rosenqvist M. The prognosis of patients with atrial fibrillation is improved when sinus rhythm is restored: report from the Stockholm Cohort of Atrial Fibrillation (SCAF). Heart 95 (2009) 1000-1005
47. Ahmed M.I., White M., Ekundayo O.J., et al. A history of atrial fibrillation and outcomes in chronic advanced systolic heart failure: a propensity-matched study. Eur Heart J 30 (2009) 2029-2037
48. Bianchi S., Rossi P., Della Scala A., et al. Atrioventricular (AV) node vagal stimulation by transvenous permanent lead implantation to modulate AV node function: safety and feasibility in humans. Heart Rhythm 6 (2009) 1282-1286
49. Hong-Wei L., Ying S., Min L., Pi-Ding L., and Zheng Z. A probability density function method for detecting atrial fibrillation using R-R intervals. Med Eng Phys 31 (2009) 116-123
50. Katsouras G., Sakabe M., Comtois P., et al. Differences in atrial fibrillation properties under vagal nerve stimulation versus atrial tachycardia remodeling. Heart Rhythm 6 (2009) 1465-1472
51. Aistrup G.L., Villuendas R., Ng J., et al. Targeted G-protein inhibition as a novel approach to decrease vagal atrial fibrillation by selective parasympathetic attenuation. Cardiovasc Res 83 (2009) 481-492
52. Fenton F.H., Luther S., Cherry E.M., et al. Termination of atrial fibrillation using pulsed low-energy far-field stimulation. Circulation 120 (2009) 467-476
53. Rossman E.I., Liu K., Morgan G.A., et al. The gap junction modifier, GAP-134 [(2S,4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic acid], improves conduction and reduces atrial fibrillation/flutter in the canine sterile pericarditis model. J Pharmacol Exp Ther 329 (2009) 1127-1133
54. Hohnloser S.H., Crijns H.J., van Eickels M., et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 360 (2009) 668-678
55. Kober L., Torp-Pedersen C., McMurray J.J., et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med 358 (2008) 2678-2687
56. Singh S.N., Tang X.C., Reda D., and Singh B.N. Systematic electrocardioversion for atrial fibrillation and role of antiarrhythmic drugs: a substudy of the SAFE-T trial. Heart Rhythm 6 (2009) 152-155
57. Kumar K., Nearing B.D., Carvas M., et al. Ranolazine exerts potent effects on atrial electrical properties and abbreviates atrial fibrillation duration in the intact porcine heart. J Cardiovasc Electrophysiol 20 (2009) 796-802
58. Sicouri S., Belardinelli L., Carlsson L., and Antzelevitch C. Potent antiarrhythmic effects of chronic amiodarone in canine pulmonary vein sleeve preparations. J Cardiovasc Electrophysiol 20 (2009) 803-810
59. Gold M.R., Adler S., Fauchier L., et al. Impact of atrial prevention pacing on atrial fibrillation burden: primary results of the Study of Atrial Fibrillation Reduction (SAFARI) trial. Heart Rhythm 6 (2009) 295-301
60. Lip G., Nieuwlaat R., Pisters R., Lane D., and Crijns H. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor based approach: the Euro Heart Survey on Atrial Fibrillation. Chest (2009) [Epub ahead of print]
61. Botto G.L., Padeletti L., Santini M., et al. Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. J Cardiovasc Electrophysiol 20 (2009) 241-248
62. Poli D., Antonucci E., Grifoni E., Abbate R., Gensini G.F., and Prisco D. Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years. J Am Coll Cardiol 54 (2009) 999-1002
63. Plesch W., and van den Besselaar A.M. Validation of the international normalized ratio (INR) in a new point-of-care system designed for home monitoring of oral anticoagulation therapy. Int J Lab Hematol 31 (2009) 20-25
64. Ricci R.P., Morichelli L., Gargaro A., Laudadio M.T., and Santini M. Home monitoring in patients with implantable cardiac devices: is there a potential reduction of stroke risk?. Results from a computer model tested through monte carlo simulations. J Cardiovasc Electrophysiol 208 (2009) 1244-1251
65. Ellis D.J., Usman M.H., Milner P.G., Canafax D.M., and Ezekowitz M.D. The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation. Circulation 120 (2009) 1029-1035 2 p following 1035
66. Connolly S.J., Pogue J., Hart R.G., et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 360 (2009) 2066-2078
67. Holmes Jr. D.R., Kereiakes D.J., Kleiman N.S., Moliterno D.J., Patti G., and Grines C.L. Combining antiplatelet and anticoagulant therapies. J Am Coll Cardiol 54 (2009) 95-109
68. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361 (2009) 1139-1151
69. Holmes D.R., Reddy V.Y., Turi Z.G., et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 374 (2009) 534-542
70. Krahn A.D., Healey J.S., Simpson C.S., Essebag V., Sivakumaran S., and Birnie D.H. Anticoagulation of patients on chronic warfarin undergoing arrhythmia device surgery: wide variability of perioperative bridging in Canada. Heart Rhythm 6 (2009) 1276-1279
71. Badger T.J., Oakes R.S., Daccarett M., et al. Temporal left atrial lesion formation after ablation of atrial fibrillation. Heart Rhythm 6 (2009) 161-168
72. Roux J.F., Zado E., Callans D.J., et al. Antiarrhythmics After Ablation of Atrial Fibrillation (5A Study). Circulation 120 (2009) 1036-1040
73. Hu Y.F., Higa S., Huang J.L., et al. Electrophysiologic characteristics and catheter ablation of focal atrial tachycardia with more than one focus. Heart Rhythm 6 (2009) 198-203
74. Bhargava M., Di Biase L., Mohanty P., et al. Impact of type of atrial fibrillation and repeat catheter ablation on long-term freedom from atrial fibrillation: results from a multicenter study. Heart Rhythm 6 (2009) 1403-1412
75. Lu Z., Scherlag B.J., Lin J., et al. Autonomic mechanism for initiation of rapid firing from atria and pulmonary veins: evidence by ablation of ganglionated plexi. Cardiovasc Res 84 (2009) 245-252
76. Po S.S., Nakagawa H., and Jackman W.M. Localization of left atrial ganglionated plexi in patients with atrial fibrillation. J Cardiovasc Electrophysiol 20 (2009) 1186-1189
77. Pokushalov E., Romanov A., Shugayev P., et al. Selective ganglionated plexi ablation for paroxysmal atrial fibrillation. Heart Rhythm 6 (2009) 1257-1264
78. Zhang Y., Ilsar I., Sabbah H.N., Ben David T., and Mazgalev T.N. Relationship between right cervical vagus nerve stimulation and atrial fibrillation inducibility: therapeutic intensities do not increase arrhythmogenesis. Heart Rhythm 6 (2009) 244-250
79. Vaitkevicius R., Saburkina I., Rysevaite K., et al. Nerve supply of the human pulmonary veins: an anatomical study. Heart Rhythm 6 (2009) 221-228
80. Esato M., Hindricks G., Sommer P., et al. Color-coded three-dimensional entrainment mapping for analysis and treatment of atrial macroreentrant tachycardia. Heart Rhythm 6 (2009) 349-358
81. Jais P., Matsuo S., Knecht S., et al. A deductive mapping strategy for atrial tachycardia following atrial fibrillation ablation: importance of localized reentry. J Cardiovasc Electrophysiol 20 (2009) 480-491
82. Lin Y.J., Higa S., Tai C.T., et al. Role of the right atrial substrate in different types of atrial arrhythmias. Heart Rhythm 6 (2009) 592-598
83. Nakazawa Y., Ashihara T., Tsutamoto T., Ito M., and Horie M. Endothelin-1 as a predictor of atrial fibrillation recurrence after pulmonary vein isolation. Heart Rhythm 6 (2009) 725-730
84. Shimano M., Shibata R., Inden Y., et al. Reactive oxidative metabolites are associated with atrial conduction disturbance in patients with atrial fibrillation. Heart Rhythm 6 (2009) 935-940
85. Nguyen B.L., Fishbein M.C., Chen L.S., Chen P.S., and Masroor S. Histopathological substrate for chronic atrial fibrillation in humans. Heart Rhythm 6 (2009) 454-460
86. Scherr D., Sharma K., Dalal D., et al. Incidence and predictors of periprocedural cerebrovascular accident in patients undergoing catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol 20 (2009) 1357-1363
87. Sauren L.D., Van Belle Y., De Roy L., et al. Transcranial measurement of cerebral microembolic signals during endocardial pulmonary vein isolation: comparison of three different ablation techniques. J Cardiovasc Electrophysiol 20 (2009) 1102-1107
88. Lin Y.J., Tai C.T., Chang S.L., et al. Efficacy of additional ablation of complex fractionated atrial electrograms for catheter ablation of nonparoxysmal atrial fibrillation. J Cardiovasc Electrophysiol 20 (2009) 607-615
89. Jacquemet V., and Henriquez C.S. Genesis of complex fractionated atrial electrograms in zones of slow conduction: a computer model of microfibrosis. Heart Rhythm 6 (2009) 803-810
90. Yamabe H., Morihisa K., Tanaka Y., et al. Mechanisms of the maintenance of atrial fibrillation: role of the complex fractionated atrial electrogram assessed by noncontact mapping. Heart Rhythm 6 (2009) 1120-1128
91. Oral H., Chugh A., Yoshida K., et al. A randomized assessment of the incremental role of ablation of complex fractionated atrial electrograms after antral pulmonary vein isolation for long-lasting persistent atrial fibrillation. J Am Coll Cardiol 53 (2009) 782-789
92. Roux J.F., Gojraty S., Bala R., et al. Effect of pulmonary vein isolation on the distribution of complex fractionated electrograms in humans. Heart Rhythm 6 (2009) 156-160
93. Scherr D., Dalal D., Cheema A., et al. Long- and short-term temporal stability of complex fractionated atrial electrograms in human left atrium during atrial fibrillation. J Cardiovasc Electrophysiol 20 (2009) 13-21
94. Tsai W.C., Lin Y.J., Tsao H.M., et al. The optimal automatic algorithm for the mapping of complex fractionated atrial electrograms in patients with atrial fibrillation. J Cardiovasc Electrophysiol 21 (2010) 21-26
95. Atienza F., Almendral J., Jalife J., et al. Real-time dominant frequency mapping and ablation of dominant frequency sites in atrial fibrillation with left-to-right frequency gradients predicts long-term maintenance of sinus rhythm. Heart Rhythm 6 (2009) 33-40
96. Ciaccio E.J., Biviano A.B., Whang W., Wit A.L., Garan H., and Coromilas J. New methods for estimating local electrical activation rate during atrial fibrillation. Heart Rhythm 6 (2009) 21-32
97. Segal O.R., Gula L.J., Skanes A.C., Krahn A.D., Yee R., and Klein G.J. Differential ventricular entrainment: a maneuver to differentiate AV node reentrant tachycardia from orthodromic reciprocating tachycardia. Heart Rhythm 6 (2009) 493-500
98. Cappato R., Calkins H., Chen S.A., et al. Prevalence and causes of fatal outcome in catheter ablation of atrial fibrillation. J Am Coll Cardiol 53 (2009) 1798-1803
99. Bunch T.J., Crandall B.G., Weiss J.P., et al. Warfarin is not needed in low-risk patients following atrial fibrillation ablation procedures. J Cardiovasc Electrophysiol 20 (2009) 988-993
100. Ellis E.R., Culler S.D., Simon A.W., and Reynolds M.R. Trends in utilization and complications of catheter ablation for atrial fibrillation in Medicare beneficiaries. Heart Rhythm 6 (2009) 1267-1273